Pharmacologically, belzutifan, a small-molecule inhibitor, acts on the PAS-B domain of HIF-2α to prohibit dimerization with ARNT, thereby inhibiting HIF-2α-mediated transcriptional programs and making it an actionable target, at least in ccRCC (9). The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.